tiprankstipranks
TScan Therapeutics Announces Promising Phase 1 Trial Results
Company Announcements

TScan Therapeutics Announces Promising Phase 1 Trial Results

Pick the best stocks and maximize your portfolio:

TScan Therapeutics ( (TCRX) ) has shared an announcement.

TScan Therapeutics has announced promising results from its ALLOHA Phase 1 trial, showing that TSC-100 and TSC-101 therapies could significantly reduce relapse in patients with acute leukemias and myelodysplastic syndromes post-transplant. The study, which enrolled 38 patients, demonstrated improved event-free survival rates for those receiving the treatment, with the therapies well-tolerated and no dose-limiting toxicities observed. Encouraged by the data, TScan plans to launch a pivotal trial in 2025, potentially expanding its market with increased use of reduced intensity conditioning and haploidentical donors.

See more insights into TCRX stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyTScan Therapeutics to present data from ongoing ALLOHA Phase 1 trial at ASH
TipRanks Auto-Generated NewsdeskTScan Therapeutics Reports Q3 2024 Financial Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App